Lookup NU author(s): Dr Mojgan Reza,
Dr Steven Laval,
Dr Andreas Roos,
Professor Hanns Lochmuller
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Duchenne muscular dystrophy (DMD) is a severe, genetic muscle disease caused by the absence of the sarcolemmal protein dystrophin. Gene replacement therapy is considered a potential strategy for the treatment of DMD, aiming to restore the missing protein. Although the elements of the dystrophin molecule have been identified and studies in transgenic mdx mice have explored the importance of a number of these structural domains, the resulting modified dystrophin protein products that have been developed so far are only partially characterized in relation to their structure and function in vivo. To optimize a dystrophin cDNA construct for therapeutic application we designed and produced four human minidystrophins within the packaging capacity of lentiviral vectors. Two novel minidystrophins retained the centrally located neuronal nitric oxide synthase (nNOS)-anchoring domain in order to achieve sarcolemmal nNOS restoration, which is lost in most internally deleted dystrophin constructs. Functionality of the resulting truncated dystrophin proteins was investigated in muscle of adult dystrophin-deficient mdx mice followed by a battery of detailed immunohistochemical and morphometric tests. This initial assessment aimed to determine the overall suitability of various constructs for cloning into lentiviral vectors for ex vivo gene delivery to stem cells for future preclinical studies.
Author(s): Reza M, Laval SH, Roos A, Carr S, Lochmuller H
Publication type: Article
Publication status: Published
Journal: Human Gene Therapy Methods
Print publication date: 01/10/2016
Online publication date: 31/07/2016
Acceptance date: 28/07/2016
ISSN (print): 1946-6536
ISSN (electronic): 1946-6544
Publisher: Mary Ann Liebert, Inc.
Altmetrics provided by Altmetric